Skye Bioscience Announces Next Generation Preclinical Abstracts of THCVHS Selected by American Association of Pharmaceutical Scientists at PharmSci 360 Meeting

SAN DIEGO, CA, September 21, 2021 (GLOBE NEWSWIRE) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary molecules derived from cannabinoids to treat diseases with high unmet needs, announced today, its research partner, the University of Mississippi, will present late-breaking preclinical data evaluating different formulations of nanoemulsions of its tetrahydrocannabinol (THC) prodrug, THCVHS, in addition to the superiority of THCVHS, to lower intraocular pressure in Dutch belted rabbits when co-administered with netarsudil, a rho-kinase inhibitor, at the American Association of Pharmaceutical Scientists Meeting (AAPS) PharmSci 360 2021 to be held from 17-20 October 2021 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Details of the latest poster presentations:

Title: IOP profile in Dutch belted rabbits after topical application of 9-tetrahydrocannabinol-valine-hemisuccinate nanoemulsion formulations (THC-VHS, NB1111)
Poster Number: M0930-06-33
Dated: Monday, October 18, 2021 9:30 a.m. to 10:30 a.m. ET

Title: Co-administration of ∆9-Tetrahydrocannabinol-Valine-Hemisuccinate (THC-VHS, NB1111) and Netarsudil, a Rho-Kinase inhibitor, produced superior IOP lowering activity in Dutch belted rabbits.
Poster Number: T0930-06-33
Dated: Tuesday, October 19, 2021 9:30 a.m. to 10:30 a.m. ET

Full summaries are available online at Posters will be available on Skye’s website after the presentations.

About the University of Mississippi
The University of Mississippi, the state’s flagship university, is in the elite group of R-1: Doctoral Universities – Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders in public service, academia, research, and business. Its 15 academic divisions include a large medical school, nationally recognized schools of accounting, law, and pharmacy, and a specialty college recognized for a blend of academic rigor, experiential learning, and opportunity. community action. Over 50 years ago, the university won the first federal government contract to cultivate cannabis for research.

About Skye Bioscience
Skye Bioscience Inc. is a biopharmaceutical company that harnesses the pharmaceutical potential of cannabinoids through the development of its proprietary molecules derived from cannabinoids to treat diseases with significant unmet needs. The company’s flagship program, THCVHS, focuses on the treatment of glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit:


Karam takhar
Vice-President, Corporate Development and Investor Relations
Email: [email protected]
Telephone: (858) 410-0266


This press release contains forward-looking statements, including statements regarding the development of our products, our business strategy, the schedule of clinical trials and the commercialization of therapeutic products derived from cannabinoids. Such statements and other statements in this press release that are not descriptions of historical fact are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or if such assumptions prove to be incorrect, our business, results of operations, financial condition and the price of our shares could be materially adversely affected. In some cases, forward-looking statements may be identified by words such as “anticipated”, “plans”, “objective”, “objective”, “objective”, “intention”, “belief”, “may”, “could” , “Cause”, “foreseeable”, “will”, “would”, “could” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. Therefore, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks which are described in the Factors section. risk of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intention or obligation to update these forward-looking statements.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *